Dr. Schmid Discusses the Findings of the IMpassion130 Trial in TNBC

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

The phase III IMpassion130 trial evaluated the efficacy and safety of the PD-L1 inhibitor atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) versus nab-paclitaxel alone in treatment-naïve patients with metastatic TNBC. Findings presented at the 2018 ESMO Congress showed that the addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1—positive disease.

The median progression-free survival in the PD-L1—positive population was 7.5 months (95% CI, 6.7-9.2) with atezolizumab plus nab-paclitaxel and 5.0 months (95% CI, 3.8-5.6) with chemotherapy (HR, 0.62; 95% CI, 0.49-0.78; P <.0001). Schmid says the addition of atezolizumab to nab-paclitaxel established a clear benefit in this population. At the time of presentation, the overall survival analysis was not statistically significant, but in the PD-L1—positive patients, there was an increase in benefit with the addition of a checkpoint inhibitor.